Atossa Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Atossa Therapeutics

13/05/2025 14:52

Atossa Therapeutics Inc ATOS.OQ reported a quarterly adjusted loss of 5 cents​​ per share for the quarter ended March 31, identical to the same quarter last year.  The mean expectation of three analysts for the quarter was for a loss of 6 cents per share. Wall Street expected results to range from -6 cents to -5 cents per share.

Reported revenue was zero​; analysts expected zero.

Atossa Therapeutics Inc's reported EPS for the quarter was a loss of 5 cents​.

The company reported a quarterly loss of $6.72 million.

Atossa Therapeutics Inc shares had risen by 24.4% this quarter and lost 11.4% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had risen by about 19% in the last three months.​

In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Atossa Therapeutics Inc is $7.00

This summary was machine generated from LSEG data May 13 at 01:52 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Mar. 31 2025
-0.06
-0.05
Beat
Dec. 31 2024
-0.06
-0.05
Beat
Sep. 30 2024
-0.06
-0.06
Met
Jun. 30 2024
-0.06
-0.05
Beat